Aytu BioScience is a specialty life sciences company focused on commercializing novel products in the field of urology. Aytu is initially concentrating on hypogonadism low testosterone , male infertility, and sexual wellness and vitality, and the company plans to expand into other urological indications for which there are significant medical needs. The company currently markets Natesto, the only FDA approved nasally administered testosterone, which is indicated for the treatment of hypogonadism. Outside the U.S., Aytu also markets the company s proprietary MiOXSYS system, a novel, point of care diagnostic system with the potential to become a standard of care as an aid in the diagnosis of male infertility. MiOXSYS is CE Marked and Health Canada approved and has been sold in over countries around the world. Aytu also markets ProstaScint, an FDA approved radioimaging agent indicated to detect prostate specific membrane antigen PSMA in the assessment and staging of prostate cancer. Aytu also acquired wholly owned subsidiary Nuelle, Inc., a personal health and wellness company focused on women s sexual wellbeing and intimacy that markets Fiera, a personal care device for women that is scientifically proven to enhance physical arousal and sexual desire.
Quote | Aytu BioPharma Inc. (NASDAQ:AYTU)
Last: | $2.79 |
---|---|
Change Percent: | -0.36% |
Open: | $2.8 |
Close: | $2.79 |
High: | $2.8326 |
Low: | $2.74 |
Volume: | 6,921 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
News | Aytu BioPharma Inc. (NASDAQ:AYTU)
2024-02-14 22:52:09 ET Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Conference Call February 14, 2024 16:30 ET Company Participants Roger Weiss - Investor Relations Joshua Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call ...
2024-02-14 16:20:46 ET More on Aytu BioScience Seeking Alpha’s Quant Rating on Aytu BioScience Historical earnings data for Aytu BioScience Financial information for Aytu BioScience Read the full article on Seeking Alpha For further details see...
Message Board Posts | Aytu BioPharma Inc. (NASDAQ:AYTU)
Subject | By | Source | When |
---|---|---|---|
AYTU BIOPHARMA: LEADING THE ADHD DRUG MARKET$AYTUExcited to share an article about Aytu BioPharma, I | 11/28/2023 7:55:36 AM | ||
But Josh got paid! Reverse split and huge | Drugdoctor | investorshub | 02/22/2023 1:52:42 PM |
whytestocks: $AYTU News Article - Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Resu | whytestocks | investorshangout | 02/21/2023 8:30:47 PM |
whytestocks: $AYTU News Article - Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescrip | whytestocks | investorshangout | 11/30/2022 4:00:55 PM |
whytestocks: $AYTU News Article - Aytu BioPharma Ranked Among Fastest-Growing Companies in North Ame | whytestocks | investorshangout | 11/17/2022 5:00:50 PM |
News, Short Squeeze, Breakout and More Instantly...
Q2 2024 operating income of $2.4 million Q2 2024 net loss of $0.2 million and adjusted EBITDA 1 of $5.1 million Q2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 million Q2 2024 ADHD Portfolio net revenue up 49% compared to Q2...
Owens Corning Inc New (OC) is expected to report $2.82 for Q4 2023 Getty Realty Corporation (GTY) is expected to report $0.56 for Q4 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q2 2024 Nexien BioPharma Inc (NXEN) is expected to report for Q2 2024 Ayt...
DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December...